App-Quantinova.ai

Risk of arterial thromboembolism in patients with colorectal cancer.

Babak B. Navi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

N/A

Polymorphisms risk modeling for vascular toxicity in patients with glioblastoma treated on NRG Oncology/RTOG 0825.

Renke Zhou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Predicting venous thromboembolism in hospitalized cancer patients: a risk assessment tool.

Rushad Patell - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Validation of a thrombosis risk assessment model in patients with newly diagnosed multiple myeloma.

Brea Lipe - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Do risks with the use of erythropoeitin stimulating agents (ESAs) differ by tumor type? Implications concerning survival and thrombosis based on meta-analysis (MA).

Vineeth Sukrithan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Low rates of symptomatic venous thromboembolism in patients with gastrointestinal cancer: an Iranian study.

Mohammad Reza Mortazavizadeh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Thrombosis in a population of phase I trial patients.

Alan D. Smith - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Update analysis: Thromboembolism in gastrointestinal tract cancer patients receiving chemotherapy.

Ayane Oba - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Risk factors and prognostic impact of venous thromboembolism (VTE) in patients (pts) with advanced gastric cancer (AGC).

Hiroyuki Arai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Edoxaban

Percutaneous electrochemotherapy of malignant main portal veins thrombosis: a prospective case series.

Luciano Tarantino - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Three-dimensional conformal radiotherapy (3D-CRT) for macroscopic vascular invasion (MVI) of advanced hepatocellular carcinoma (HCC).

Akinori Asagi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

tPA as marker of thrombosis development after surgical treatment for pancreatic cancer.

Umar Muhmadovich Gaziev - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Venous thromboembolism in metastatic urothelial carcinoma.

Patrik Palacka - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): A Global Germ Cell Cancer Group (G3) Study.

Ben Tran - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Natural history of heparin-induced thrombocytopenia (HIT) in the cancer population.

Myra Pearl Wong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Heparin

Pharmacoeconomic analysis of dalteparin vs. vitamin k antagonists (VKA) for the prevention of recurrent venous thromboembolism (VTE) in cancer patients with renal insufficiency.

George Dranitsaris - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

dalteparin Subcutaneous

Pooled analysis of venous thromboembolism (VTE) from four trials of necitumumab and chemotherapy for stage IV non-small cell lung cancer (NSCLC).

Kelvin Young - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Carboplatin

Low molecular weight heparin (LMWH) use in patients with hematologic malignancy-associated venous thromboembolism (VTE) and severe thrombocytopenia.

Nabin Khanal - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

Thrombus formation inside liver metastasis of breast cancer by pegylated liposomal doxorubicin

Megumi Kai - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Doxorubicin Hydrochloride

Venous thromboembolism in patients with glioblastoma multiforme.

Natasha Edwin - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Filters

7277 Abstracts